Charles River Laboratories International (CRL)
(Delayed Data from NYSE)
$232.10 USD
+3.07 (1.34%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $232.27 +0.17 (0.07%) 7:42 PM ET
3-Hold of 5 3
C Value C Growth B Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CRL 232.10 +3.07(1.34%)
Will CRL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CRL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRL
ICLR vs. CRL: Which Stock Is the Better Value Option?
Teladoc (TDOC) Reports Q1 Loss, Tops Revenue Estimates
CRL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Charles River (CRL) to Report Q1 Earnings: Here's What to Expect
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Other News for CRL
The “highest quality” stocks within each sector - GS
Iterum Therapeutics resubmits new drug application to U.S. FDA for oral sulopenem
With rate cuts pushed out, Goldman looks at quality stocks
Danaher Q1: The Worst Time Has Already Passed
Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally